# Ottimo Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ottimo-pharma

- Industry: Biotechnology
- Headquarters: Kent, UK
- Website: www.ottimopharma.com/
- Total disclosed funding: $142M
- Latest round: Series A (Dec 18, 2024)
- Investors on record: 9

## About

Founded in 2020, and based in the UK, Ottimo Pharma is dedicated to the creation of advanced cancer therapeutics. The company raised USD 140.00 mn in a Series A round co-led by Avoro Capital Advisors, OrbiMed Advisors, and Samsara BioCapital on December 19, 2024, with other notable investors participating. The founder has a background in the biotech industry, although specific prior ventures are not disclosed. Medicxi and Jonny Finlay co-founded the firm. David Epstein is leading the firm as CEO as of 2024.

Ottimo Pharma is engaged in the development of bifunctional medicines that target the PD1 and VEGFR2 pathways, essential in cancer treatment. Their therapeutics are designed to offer a wide therapeutic index for treatment with reduced toxicity, aimed at extending the lives of cancer patients. The primary beneficiaries of these products include oncologists and healthcare institutions, with ongoing evaluations in clinical settings across North America, Europe, and parts of Asia. 

Ottimo Pharma's revenue generation model is built on partnerships with healthcare providers and research institutions to support the development and commercialization of its bifunctional medicines. 

Ottimo Pharma plans to utilize the recent funding of USD 140.00 mn to advance its lead molecule, Jankistomig, and develop additional bifunctional assets. The company is targeting the expansion of its product offerings into new markets, specifically aiming to reach more healthcare providers in North America, Europe, and parts of Asia by the end of 2025. The strategic funding will allow Ottimo Pharma to enhance its research capabilities and accelerate the launch of innovative products in oncology.

## Funding rounds

- Series A, Dec 18, 2024, $142M — OrbiMed Advisors, Invus [DUP], J.P. Morgan, Decheng Capital, RTW Investments, Janus Henderson Investors, Medicxi, Samsara BioCapital, Avoro Capital Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Invus [DUP] — Series A
- J.P. Morgan — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A
- Janus Henderson Investors — Series A
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- Avoro Capital Advisors — Series A